Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Anti-obesity agents

Liraglutide has positive effects on bone metabolism in obese women

Glucagon-like peptide 1 (GLP-1) receptor agonists are used to treat type 2 diabetes mellitus and one such agent, liraglutide, has recently been approved for use as an anti-obesity drug. In the image, an obese woman walks on the pavement

Source: Dreamstime.com

Women treated with liraglutide had increased levels of a bone formation marker

Glucagon-like peptide 1 (GLP-1) receptor agonists are used to treat type 2 diabetes mellitus and one such agent, liraglutide, has recently been approved for use as an anti-obesity drug. Preclinical studies suggest that GLP-1 regulates bone turnover but the effect of GLP-1 receptor agonists on bone metabolism in obese patients is unknown.

Researchers studied 37 healthy obese women with a mean body mass index of 34 who followed a very-low-calorie diet for eight weeks before being randomised to receive liraglutide 1.2mg/day or not for 52 weeks. Both groups of women maintained their pre-randomisation weight loss but women in the control group experienced greater loss of bone mineral content than liraglutide-treated women, who also had increased levels of a bone formation marker.

The findings emphasise the potential of liraglutide as a “relevant and safe antiobesity drug”, say the researchers in Journal of Clinical Endocrinology & Metabolism[1] (online, 4 June 2015). 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068804

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.